MIRA Pharmaceuticals’ MIRA-55 Formulation Shows Favorable Bioavailability and Tissue Distribution
MIRA•MIRA Pharmaceuticals’ optimized oral MIRA-55 formulation demonstrated favorable bioavailability along with sustained systemic exposure and reproducible brain and liver distribution in preclinical pharmacokinetic studies. These results support advancing the non-opioid therapy candidate toward further preclinical development for chronic inflammatory pain.
1. Preclinical Formulation Results
MIRA Pharmaceuticals tested multiple oral formulations of MIRA-55 in a preclinical pharmacokinetic study, selecting a lead candidate that achieved favorable oral bioavailability, sustained systemic drug levels and reproducible distribution into both brain and liver tissues.
2. Pharmacokinetic Profile and Tissue Distribution
The chosen formulation delivered pharmacologically relevant concentrations in central and peripheral sites, with brain exposure supporting modulation of pain pathways and liver distribution reinforcing anti-inflammatory activity seen in earlier efficacy models.
3. Implications for Clinical Development
These pharmacokinetic findings validate the oral delivery strategy for MIRA-55, de-risking formulation challenges and strengthening the candidate’s profile as a differentiated non-opioid therapy for chronic inflammatory pain ahead of IND-enabling work.
4. Next Steps
The company will continue evaluating the relationship between tissue exposure, pharmacodynamics and therapeutic efficacy as MIRA-55 advances through additional preclinical safety studies and preparation for first-in-human trials.
